ROIV News and Press, Roivant Sciences Ltd. From 06/28/23

2023-06-28 07:24:17 ET Roivant Sciences press release ( NASDAQ: ROIV ): Q4 GAAP EPS of -$0.20 beats by $0.18 . Revenue of $27.38M (+197.0% Y/Y) beats by $9.18M . For further details see: Roivant Sciences GAAP EPS of -$0.20 beats by $0.18, revenue of $27.3...

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses A Phase 2 study of RVT-3101 in Crohn’s disease has been initiated with to...

2023-06-27 11:38:29 ET Roivant Sciences ( NASDAQ: ROIV ) is scheduled to announce FQ4 earnings results on Wednesday, June 28th, before market open. The consensus EPS Estimate is -$0.32 (+17.9% Y/Y) and the consensus Revenue Estimate is $18.2M (+97.4% Y/Y). Over the las...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fis...

2023-06-22 11:41:01 ET Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data for its midstage ulcerative colitis therapy, RVT-3101. RVT-3...

2023-06-22 08:32:13 ET Roivant Sciences ( NASDAQ: ROIV ) added ~12% pre-market Thursday after the U.K.-based biotech announced long-term data from a Phase 2b trial for its once-monthly subcutaneous therapy, RVT-3101, targeted at ulcerative colitis. Citing 56-week data from t...

This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission 1 (36% at week 56 vs. 29% at week 14) and Endoscopic Improvement 2 ...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Pha...

2023-06-13 04:32:53 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased to $21.31B in Q1 2023, with Visa, McKesson, UnitedHealth, Elevance Health, and General Electric as the largest holdings. New stakes were established in Lululemon Athletica, Sherwin-Williams,...

2023-06-12 03:54:39 ET Summary Roivant Sciences exhibits a strong financial outlook, backed by its substantial cash position, strategic acquisitions, and efficient R&D expense management. The company's innovative drug pipeline includes the breakthrough product VTAMA for atopic...